Scientific Library of Tomsk State University

   E-catalog        

Normal view MARC view

Molecular Vaccines electronic resource From Prophylaxis to Therapy - Volume 2 / edited by Matthias Giese.

Contributor(s): Giese, Matthias [editor.] | SpringerLink (Online service)Material type: TextTextPublication details: Cham : Springer International Publishing : Imprint: Springer, 2014Description: XXVIII, 870 p. 98 illus., 74 illus. in color. online resourceContent type: text Media type: computer Carrier type: online resourceISBN: 9783319009780Subject(s): medicine | Immunology | Vaccines | Biomedicine | Vaccine | Immunology | Molecular MedicineDDC classification: 615.372 LOC classification: RM281QR189-189.5Online resources: Click here to access online
Contents:
Non-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration.
In: Springer eBooksSummary: This title discusses all aspects of non-infectious and non-cancer– so called NINC – vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application.
Tags from this library: No tags from this library for this title. Log in to add tags.
No physical items for this record

Non-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration.

This title discusses all aspects of non-infectious and non-cancer– so called NINC – vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application.

There are no comments on this title.

to post a comment.
Share